HeartBeam Inc. (NASDAQ: BEAT), a medical technology company specializing in cardiac care, has become a contributing partner in EXIT-CVD, a European cardiovascular research initiative co-funded by the European Union Innovative Health Initiative and industry partners. The consortium, led by University Medical Center Groningen and Royal Philips, unites 42 organizations across 17 countries to conduct 22 clinical studies involving over 14,000 patients, backed by a total budget of 27.6 million euros. As part of this initiative, HeartBeam will lead the HEART-CHECK study, which will evaluate its portable electrocardiogram (ECG) system for early detection and triage of cardiac events in high-risk patients recently discharged after acute coronary syndrome. The study aims to assess the system's clinical performance and its integration into real-world care pathways.
This announcement carries significant implications for both HeartBeam and the broader landscape of cardiac care. By participating in a large-scale, EU-funded research consortium, HeartBeam gains access to a diverse patient population and a collaborative network of leading medical institutions. The HEART-CHECK study will generate critical clinical evidence that could accelerate the adoption of HeartBeam's technology in Europe and beyond. The portable ECG system, which recently received U.S. Food and Drug Administration Breakthrough Device Designation for at-home heart attack assessment, is designed to provide actionable heart intelligence outside traditional medical facilities. If the study demonstrates strong clinical performance, it could pave the way for regulatory approvals and reimbursement in European markets, opening a substantial new revenue opportunity for the company.
Furthermore, the HEART-CHECK study focuses on patients discharged after acute coronary syndrome, a group at high risk for recurrent cardiac events. Early detection and triage using HeartBeam's technology could lead to faster intervention, reduced hospital readmissions, and improved patient outcomes. This aligns with the broader goals of EXIT-CVD, which seeks to revolutionize cardiovascular care through innovative technologies and collaborative research. For investors, HeartBeam's involvement in such a high-profile initiative underscores its potential to become a key player in the global cardiac monitoring market. The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, forms the foundation of its portable system. The HEART-CHECK study will further validate this technology in a real-world setting, potentially strengthening its competitive position.
The latest news and updates relating to HeartBeam are available in the company's newsroom at https://ibn.fm/BEAT. For details on the intended use of its technology, refer to the company's Cleared Indications for Use. InvestorWire, a specialized communications platform, distributed this announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers services including editorial syndication to 5,000+ outlets and social media distribution. For more information, visit InvestorWire.


